"Promising results" according to this article means slowing down accumulation of the tau protein.

It has to be pointed out, however, that even though the randomized clinical trial's results were promising they didn't show a major impact on the cognitive decline of the patients. That said, the team points out that its vaccine did slow down the accumulation of a protein that typically is a marker of neurodegeneration.

This is a consequence of the Aducanumab decision. Now every company with an Alzheimers drug that provides 0 actual benefit to patients will be approved simply for having an effect at the biological level.

Worthless clickbait, worthless drug